Log inStart free trialBook a demo
Log inStart free trial
Media Database
>
Stephen Hansen

Stephen Hansen

Associate Editor at BioCentury

Contact this person
Email address
s*****@*******.comGet email address
Influence score
36
Phone
(XXX) XXX-XXXX Get mobile number
Location
United Kingdom
Languages
  • English
Covering topics
  • Finance & Banking Services
  • Workplace

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

biocentury.com

U.K. budget boosts venture funding but raises costs for lab space

The U.K. government’s autumn budget loosened restrictions on how much VC funds can invest and expanded eligibility for employee share-option plans &...
26 days ago
biocentury.com

FDA’s moving goalposts & China’s innovation arc — a BioCentury podcast

A baffling FDA decision to issue a complete response letter for a pediatric medicine that physicians supported is the latest example fueling concerns that ...
28 days ago
biocentury.com

Cautious optimism and M&A momentum — A BioCentury podcast

There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition of th...
about 1 month ago
biocentury.com

NLRP3 for obesity: Real or mirage?

In February 2024, an unexpected preclinical finding — NLRP3 inhibition led to monotherapy effects in obesity models — sent biotechs raci...
about 1 month ago
biocentury.com

Pfizer’s Metsera win unlikely to read through to cross-border biote...

Pfizer has won the bidding war for obesity play Metsera by matching Novo Nordisk’s $10 billion offer, but the outcome doesn’t necessaril...
about 1 month ago
biocentury.com

Intrigue builds as Novo goes public with higher Metsera bid

Five weeks after it appeared that Pfizer was getting back into the obesity race via its acquisition of Metsera for up to $7.3 billion, those ambitions...
about 2 months ago
biocentury.com

Brain shuttles, GSK Q&A and FDA vouchers — a BioCentury podcast

Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAbs in par...
2 months ago
biocentury.com

What happens to biotech if the AI bubble bursts? A Perspective

By the numbers, biotech had a strong 3Q25, with indexes outperforming the broader markets and tech as M&A continued to ramp up. Yet with specialist hea...
2 months ago
biocentury.com

Market indicators: Déjà vu all over again

The fourth quarter has begun with a familiar feeling. A suite of indicators once again points to an improving public market for biopharma companies, but un...
2 months ago
biocentury.com

Insmed’s journey to the top

Nearing the end of 3Q25, Insmed is one of the most valuable biotechs in the world and on the precipice of launching what are projected to be multiple billi...
3 months ago
biocentury.com

Pipeline setbacks add to Novo’s challenges

Novo Nordisk announced a series of program terminations and trial failures Wednesday, including two that stemmed from some of the pharma’s most rece...
5 months ago